Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
That’s greats news
'Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that the Biomedical Advanced Research and Development Authority (‘BARDA’) has increased the total value of its award for the clinical and regulatory development of Summit’s precision antibiotic ridinilazole for the treatment of C. difficile infection (‘CDI’) to up to $63.7 million.'
http://www.globenewswire.com/news-release/2019/06/18/1870133/0/en/Increased-BARDA-Award-and-Option-Exercise.html
Thanks Chris - look forward to hearing how it goes, and as you say they can't really give any substantial updates without an RNS... hopefully we'll start seeing a recovery soon..
Hi PharmaGiles - Yes I am going to the AGM this week & will feed back how it went but I am not expecting any news but it will be good to talk one to one & hear questions from other shareholders.
Hi Chris - are you by any chance going to the AGM? May (hopefully) be some new updates there? Unfortunately I can't attend..
Could we be in for a surprise RNS soon in which it is announced that Summit will receive further funding for their C-Diff trials based on recent articles for the need to combat diseases like C-Diff there was a final realisation that their drug must succeed & so funds provided.Just a thought.
What a fak
A Critical Juncture for Antibiotic R&D
Jun 11, 2019
By David Roblin
Pharmaceutical Executive
Volume 39, Issue 6
http://www.pharmexec.com/critical-juncture-antibiotic-rd
In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae: future treatment option for gonorrhoea?
https://academic.oup.com/jac/article/74/6/1591/5333163
Edit: Looks good
Daily chart I suggests this area is resistance and it will be going up again soon, but new to this so don’t bank on it.
Thanks! Could well gain traction soon here
Hi stew200 - I do not think that we will see a great rush to Buy on Monday but momentum is building but you never know.
What do you think the share price will do next week?
Per Bermudashorts from the other board:
Nice mention for Ridinilazole here:-
'But there is an answer. In fact, two. One is a drug called Fidaxomicin – very expensive and definitely not government subsidized. The other, the one in which researchers including Riley hold great hope, is a new drug Ridinilazole.
Ridinilazole is now in Phase-3 clinical trials and is expected to become available in about two years.'
https://cosmosmagazine.com/biology/the-looming-threat-of-c-diff
RNS Out this evening
Annual Report & Accounts Y/E 31st January 2019 (AGM 19th June)
https://www.summitplc.com/app/uploads/2019/05/2019_Summit-Therapeutics-AR.pdf
I try not to comment unless invested and that is the case here. I purchased 10,000 after the initial biggish drop and then another 10,000 a couple of weeks back overall still slightly down but content to hold as I think the company will be purchased by one of the Big Pharma outfits.
In short, I do not think SUMM will have to develop and take their products to market on their own and while it is a risky bet it could be a lucrative one.
Surely summit is in the right place to capitalise
https://www.ft.com/content/4da1c6e4-603d-11e9-9300-0becfc937c37
Article in the FT by someone from the Welcome Trust
"The tragedy is not that investors have lost their money. Rather, it is the signal that there is no viable route to market for new antibiotics, however valuable they may be to society. Capital-starved smaller companies will fold. Innovation will die on the vine. Money already invested by governments and charities will be squandered."
but can you trust the BOD ?
https://www.summitplc.com/app/uploads/2018/06/summitra2008.pdf
I was here a long time ago. and made a few bob. But where is the update on the Orient pharma collaboration, or the TB licence to Lilly. been waiting 10 years and no news. very selective with their news releases her. DYOR
A further article:
Summit Therapeutics well placed in the race to find next-generation antibiotic
https://www.proactiveinvestors.co.uk/news/details/218703/summit-therapeutics-well-placed-in-the-race-to-find-next-generation-antibiotic-218703.html
Apparently so! Glad I purchased more last week!
Tried to buy 2 packages of 6,000 shares for our childrens SIPs and had to leave a fill or kill order as HL unable to offer a price. Suggests market makers busy this morning trading SUMM? Or HL a crap platform? I believe the former, the RNS promising, that said what works on animals might not pass phase three trials on humans.
Glad to be in on this product at these prices and optimistic.
Surely the presentation over the weekend must mean Buy now before it is too late.
What a funny time to announce it on a Sunday